Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25228532.
- Also identified by DOI 10.1158/1078-0432.CCR-14-2306 and PMC identifier 4401422.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mutations in ALK are a common mechanism of acquired resistance to small molecule ALK inhibitors in ALK-rearranged lung cancer. Different mutants exhibit differential sensitivity to ALK inhibitors. Matching the mutational profile of the tumor with the appropriate ALK inhibitor is likely to be important to maximize benefit for patients.
Medical subject headings
- Carbazoles
- Drug Resistance, Neoplasm
- Mutation
- Piperidines
- Protein Kinase Inhibitors
- Receptor Protein-Tyrosine Kinases